VIP Protocol: Complete Cycling & Dosing Guide

Overview

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide administered via nasal insufflation or subcutaneous/intramuscular injection for research and investigational therapeutic purposes. This guide addresses practical administration protocols for individuals working with qualified physicians or compounding pharmacies.

VIP operates through VPAC1 and VPAC2 G-protein coupled receptors, increasing intracellular cAMP and driving anti-inflammatory signaling. Its primary applications in current research contexts include chronic inflammatory response syndrome (CIRS), mast cell activation disorders, post-viral syndromes, and neuroinflammatory conditions.

Critical Note: VIP is not FDA-approved as a therapeutic agent in the United States and is obtained exclusively through compounding pharmacies under physician supervision. This guide is educational content only and does not constitute medical advice. All use must occur under direct physician oversight.

Standard Protocol

Nasal Administration Protocol

Dosing: 50 mcg per nostril (100 mcg total per dose)
Frequency: 4 times daily
Standard Cycle: 8–12 weeks continuous, followed by 2–4 week break

Timing Considerations:

• Administer approximately 6 hours apart (e.g., 6 AM, 12 PM, 6 PM, 12 AM)
• Evening dose should occur 1–2 hours before bed to avoid sleep disruption from transient hypotension
• Consistent timing optimizes immune modulation and circadian synchronization

Injectable Administration Protocol

Dosing Range: 25–100 mcg
Frequency: Once to twice daily
Standard Cycle: 8–12 weeks continuous, followed by 2–4 week break

Injection Timing:

• Single daily injection typically administered in morning
• Twice-daily dosing (if used) spaced 12 hours apart
• Rotate injection sites to prevent lipodystrophy

Standard Dose Selection:

• Initiate at 25 mcg daily for inflammatory conditions
• Progress to 50 mcg daily after 1–2 weeks of tolerance assessment
• Advanced protocols may utilize 75–100 mcg daily based on clinical response

Goal-Specific Protocols

Protocol A: Chronic Inflammation & Immune Dysregulation (CIRS/MCAS)

Primary Indication: Reducing neuroinflammation and restoring immune homeostasis

Recommended Route: Nasal (superior bioavailability for CNS penetration)

Dosing Structure:

• Weeks 1–2: 50 mcg per nostril, 2× daily (morning and evening)
• Weeks 3–12: 50 mcg per nostril, 4× daily (standard protocol)

Cycle: 12 weeks continuous + 3-week break before reassessing

Markers of Effectiveness:

• Reduction in inflammatory symptoms by week 3–4
• Improved cognitive clarity by week 4–6
• Decreased frequency/severity of mast cell activation episodes by week 6–8

Adjustment Protocol:

• If adequate response by week 6: maintain 4× daily dosing
• If inadequate response by week 8: consult physician regarding dose escalation or injectable route
• If excessive facial flushing/hypotension: reduce to 3× daily dosing

Protocol B: Post-Viral Conditions & Long COVID

Primary Indication: Neuroinflammation, dysautonomia, and immune restoration

Recommended Route: Nasal for initial 6 weeks; transition to injectable if persistent hypotension occurs

Dosing Structure:

• Weeks 1–3: 50 mcg per nostril, 2× daily
• Weeks 4–8: 50 mcg per nostril, 3× daily
• Weeks 9–12: 50 mcg per nostril, 4× daily

Cycle: 12 weeks + 4-week break

Dysautonomia-Specific Adjustments:

• If orthostatic intolerance worsens: reduce frequency to 2–3× daily and increase salt/fluid intake
• Monitor blood pressure before and 30 minutes after nasal administration
• Evening dose should be 2–3 hours before bed to minimize nighttime hypotension
• Consider injectable route if nasal-induced hypotension persists

Protocol C: Joint Health & Osteoarthritis

Primary Indication: Cartilage preservation and anti-inflammatory effects on synovial tissue

Recommended Route: Injectable (more consistent systemic exposure)

Dosing Structure:

• Weeks 1–4: 25 mcg once daily
• Weeks 5–12: 50 mcg once daily
• Optional: Week 12 escalation to 75 mcg if well-tolerated

Cycle: 12 weeks continuous + 3-week break

Supporting Protocols:

• Stack with collagen peptides (10–20 g daily)
• Concurrent low-intensity mobility work 5–6 days/week
• Consider anti-inflammatory diet emphasis during cycle

Assessment Timeline:

• Week 4: Initial reduction in joint discomfort
• Week 8: Noticeable improvement in morning stiffness
• Week 12: Sustained improvement in range of motion and pain scores

Protocol D: Neuroprotection & Cognitive Health

Primary Indication: Neurorestoration and anti-inflammatory CNS effects

Recommended Route: Nasal (superior blood-brain barrier penetration)

Dosing Structure:

• Weeks 1–2: 50 mcg per nostril, 2× daily (morning, evening)
• Weeks 3–12: 50 mcg per nostril, 3× daily (8 AM, 2 PM, 8 PM)

Cycle: 12 weeks continuous + 3-week break

Cognitive Markers:

• Week 2–3: Subtle improvements in mental clarity
• Week 4–6: Enhanced focus and reduced brain fog
• Week 8–12: Improved memory consolidation and processing speed

How to Administer Step-by-Step

Nasal Administration

Equipment Needed:

• Reconstituted VIP solution in pharmaceutical-grade nasal spray bottle or dropper
• Facial tissue
• Timer (for tracking intervals)

Step-by-Step Protocol:

1. Preparation: Blow nose gently to clear nasal passages. Do not forcefully clear sinuses as this may disrupt mucosal integrity.

2. Positioning: Sit upright or tilt head slightly forward. Do not tilt head back as this promotes oropharyngeal drainage.

3. Application: Dispense 50 mcg (typically 1 spray or 1 measured drop) into one nostril. Repeat for contralateral nostril for 100 mcg total dose.

4. Timing: Set phone reminder for next scheduled dose (typically 6-hour intervals for 4× daily protocol).

5. Side Effect Monitoring: Note any facial flushing, warmth, lightheadedness, or nasal irritation. Document onset and duration (typically resolves within 5–15 minutes).

6. Activity Restriction: Sit or recline for 5 minutes post-administration to minimize hypotension effects.

Injectable Administration

Equipment Needed:

• Sterile reconstitution vial containing VIP peptide powder
• Bacteriostatic water or sterile saline (as supplied by compounding pharmacy)
• 1 mL insulin syringe with 28–31 gauge needle
• Alcohol prep pads
• Sharps container

Reconstitution Protocol:

1. Calculation: Verify dose concentration with pharmacy documentation (e.g., if vial contains 500 mcg in 5 mL reconstitution volume, then 1 mL = 100 mcg).

2. Asepsis: Clean rubber septum of vial with alcohol pad using firm circular motions for 10 seconds. Allow to air dry completely.

3. Reconstitution: Draw bacteriostatic water/saline into syringe. Inject slowly into vial at an angle to minimize foaming. Gently swirl (do not shake vigorously) for 30–60 seconds until powder dissolves completely. Solution should be clear.

4. Storage: Refrigerate reconstituted solution at 2–8°C. Most compounding pharmacies recommend use within 14–28 days (verify with pharmacy documentation).

5. Pre-Injection: Remove from refrigeration 5 minutes before injection to reach room temperature. Draw prescribed dose (e.g., 50 mcg = 0.5 mL if concentration is 100 mcg/mL).

6. Injection Site Preparation: Clean skin with alcohol pad using circular motions. Allow to dry completely (minimum 10 seconds).

7. Injection Technique: Pinch 1–2 inches of skin, insert needle at 45–90 degree angle, and slowly depress plunger. Common sites: lateral deltoid, lateral thigh, or lower abdomen.

8. Post-Injection: Apply light pressure to injection site with sterile gauze for 10 seconds. Do not massage injection site.

Cycle Example: 12-Week Standard Protocol

Weeks 1–2: Initiation Phase

Nasal Protocol:

• Dose: 50 mcg per nostril, 2× daily (100 mcg total per dose)
• Timing: 8 AM, 8 PM
• Goals: Assess tolerance, establish baseline side effect profile
• Side Effect Monitoring: Track facial flushing, hypotension, nasal irritation

Key Actions:

• Establish symptom baseline (energy, inflammation markers, mood)
• Set phone reminders for consistent timing
• Review blood pressure at rest and post-administration

Weeks 3–8: Main Protocol Phase

Nasal Protocol:

• Dose: 50 mcg per nostril, 4× daily (100 mcg per dose × 4)
• Timing: 6 AM, 12 PM, 6 PM, 12 AM (midnight)
• Goals: Maximize anti-inflammatory and immunomodulatory effects
• Side Effect Monitoring: Continue tracking; most side effects should diminish

Key Actions:

• Assess efficacy at week 4 (reduced inflammation/symptoms?)
• Adjust evening timing if sleep disruption occurs
• Monitor blood pressure trends
• Begin noting subjective improvements in primary outcome measure

Weeks 9–12: Optimization Phase

Nasal Protocol:

• Dose: 50 mcg per nostril, 4× daily
• Timing: Maintain established schedule
• Goals: Consolidate therapeutic gains, identify sustained improvements
• Side Effect Monitoring: Document resolution timeline for any adverse effects

Key Actions:

• Week 10 Assessment: Quantify improvements in target outcome (pain scores, cognitive function, inflammatory markers if available)
• If inadequate response: Consult physician regarding injectable transition or dose escalation
• If excellent response: Plan continuation beyond 12 weeks (optional) or initiate 3-week washout

Weeks 13–15: Washout Phase

Protocol:

• Complete cessation of VIP administration
• Continue standard anti-inflammatory supportive care
• Monitor for symptom rebound or sustained improvement

Key Actions:

• Document whether improvements persist during washout
• Persistent improvements suggest establishment of immune tolerance/homeostasis
• Rebound symptoms suggest need for extended cycling strategy

What to Expect: Timeline of Effects

Days 1–3 (Acute Phase)

Expected Observations:

• Facial flushing and warmth immediately following nasal administration (within 2–5 minutes)
• Transient lightheadedness or dizziness, particularly with 4× daily dosing
• Mild nasal irritation or congestion
• Possible mild headache 30–60 minutes post-administration

Normal Response: These effects are dose-dependent and typically resolve within 5–30 minutes. If effects persist beyond 1 hour, dose reduction may be indicated.

Days 4–7 (Accommodation Phase)

Expected Observations:

• Reduction in acute side effect severity as physiological accommodation occurs
• Possible initial worsening of inflammatory symptoms (Jarisch-Herxheimer-like response) in some individuals
• Improved sleep quality (particularly if nasal VIP is dosed early evening)
• Subtle mood stabilization

Week 2 (Early Efficacy Phase)

Expected Observations:

• Noticeably reduced inflammatory symptoms (joint pain, brain fog, post-viral malaise)
• Improved mental clarity and focus
• Reduction in frequency/severity of mast cell symptoms if applicable
• Possible continued facial flushing with each dose

Assessment Point: If no improvement by end of week 2, verify correct administration technique and dosing with compounding pharmacy.

Weeks 3–6 (Efficacy Consolidation Phase)

Expected Observations:

• Continued improvement in primary inflammatory markers
• Enhanced cognitive function and emotional stability
• Reduced dysautonomia symptoms (if applicable)
• Normalization of sleep/wake cycles
• Diminishing facial flushing and transient hypotension

Measurable Indicators:

• Reduced visual analog pain scale scores (if applicable)
• Improved functional capacity (ability to exercise, work without fatigue)
• Normalized temperature regulation
• Improved digestion and gut motility

Weeks 7–12 (Sustained Improvement Phase)

Expected Observations:

• Plateau of therapeutic effects (continued benefit without escalating improvement)
• Near-complete resolution of acute side effects
• Establishment of new baseline inflammatory state (improved versus pre-treatment)
• Potential continued gains in cognitive function and neurological symptoms

Late-Stage Assessment: By week 10, evaluate whether continued treatment beyond 12 weeks is beneficial or whether a washout phase should begin.

Weeks 13+ (Post-Cessation Phase)

Expected Observations:

• Sustained improvement from weeks 1–12 (suggesting durable immune remodeling)
• OR gradual rebound of symptoms over 2–4 weeks (suggesting need for repeated cycles)
• Absence of withdrawal effects (VIP has no known withdrawal syndrome)

Common Protocol Mistakes

Mistake 1: Inconsistent Timing

Error: Dosing at highly variable times (e.g., 6 AM one day, 9 AM the next).

Impact: Disrupted cAMP-mediated signaling and circadian entrainment. Reduced efficacy for immune homeostasis restoration.

Correction: Set phone alarms for all four daily doses. Use a pill organizer or pre-filled nasal spray bottles to ensure consistent administration.

Mistake 2: Excessive Dose Escalation

Error: Increasing from 100 mcg to 200 mcg daily due to impatience with early progress.

Impact: Exacerbated hypotension, facial flushing, nausea, and potential cardiovascular stress without proportional efficacy gains.

Correction: Adhere to 50 mcg per nostril dosing for nasal route. If response is inadequate after 8 weeks, transition to injectable route with physician consultation rather than escalating nasal dose beyond standard protocol.

Mistake 3: Evening Dosing Too Late

Error: Administering final VIP dose at bedtime (11 PM–12 AM) without accounting for hypotensive effects.

Impact: Orthostatic hypotension upon waking, dizziness, potential falls.

Correction: Administer final daily dose 1–2 hours before sleep. If using midnight dose, ensure supine position during sleep.

Mistake 4: Inadequate Hydration & Sodium

Error: Not increasing salt and water intake during VIP cycle, particularly in individuals with dysautonomia.

Impact: Exacerbated hypotension, lightheadedness, diminished therapeutic efficacy.

Correction: Increase daily sodium intake by 1–2 grams (salt added to meals) and maintain 3–4 liters daily water intake during 12-week cycle.

Mistake 5: Poor Nasal Technique

Error: Tilting head back after nasal administration, forcing nasal passages to clear, or using excessive spray pressure.

Impact: Reduced mucosal absorption, loss of peptide to oropharynx, and unnecessary nasal irritation.

Correction: Maintain upright posture, allow solution to remain in nasal cavity for 2–3 minutes, and use gentle dispenser pressure.

Mistake 6: Premature Cycle Cessation

Error: Stopping VIP administration after 4–6 weeks due to transient side effects or perceived lack of progress.

Impact: Failure to achieve therapeutic immune remodeling, which typically requires 8–12 weeks for consolidation.

Correction: Commit to minimum 8-week cycle. If side effects are intolerable, reduce frequency (e.g., 2× or 3× daily) rather than ceasing entirely.

Mistake 7: Stacking with Immun